“Despite recent setbacks including the loss of a key contract and earnings downgrades from facility cost overruns, the manager remains bullish on EBOS. They believe the company's long-term competitive position as a leading pharmaceutical distributor remains intact, and the current valuation offers a deep 34% discount to historical multiples.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.